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The aim of this study was to assess the effect of Brewers’ yeast extract (BYE) on daily activity in a
mouse model of chronic fatigue syndrome (CFS). CFS was induced by repeated injection of Brucella
abortus (BA) antigen every 2 weeks. BYE was orally administered to mice in a dose of 2 g per kg per
day for 2 weeks before injecting BA and for 4 weeks thereafter. We evaluated daily running activity
in mice receiving BYE as compared with that in untreated mice. Weekly variation of body weight
(BW) and survival in both groups was monitored during the observation period. Spleen weight (SW),
SW/BW ratio, percent splenic follicular area and expression levels of interferon-g (IFN-g) and
interleukin-10 (IL-10) mRNA in spleen were determined in both groups at the time of sacrifice. The
daily activity during 2 weeks after the second BA injection was significantly higher in the treated group
than in the control. There was no difference in BW between both groups through the experimental
course. Two mice in the control died 2 and 7 days after the second injection, whereas no mice in the
treated group died. Significantly decreased SW and SW/BW ratio were observed in the treated mice
together with elevation of splenic follicular area. There were suppressed IFN-g and IL-10 mRNA levels
in spleens from the treated mice. Our results suggest that BYE might have a protective effect on
the marked reduction in activity following repeated BA injection via normalization of host immune
responses.
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Introduction
Fatigue is a common clinical feature in subjects with various
immunologic disorders or infectious diseases (1). However,
the pathophysiology of fatigue status is still unclear. Several
cytokines produced during the immune response to infection
are described to be mediators of some symptoms including
fever, somnolence, lymphadenopathy and appetite loss (2). It
is suggested that these cytokines also have a role in eliciting
such fatigue condition (3).
Chronic fatigue syndrome (CFS) is an incapacitating illness
defined by disabling chronic fatigue and characteristic accom-
panying signs (4). A reduction in daily activity >50% for at
least 6 months is a major criterion for diagnosis of CFS (5).
Hypotheses about the etiology of CFS propose the involve-
ment of a specific bacterial or viral infection and immune dys-
function associated with the infection. Previous research
described an immunologic model of CFS induced by intraperi-
toneal administration of bacterial antigen; however, the dura-
tion of fatigue condition evaluated by wheel running was
shown to be short (6). Ottenweller et al. (7) have reported the
establishment of a mouse model of CFS which could be
induced by Brucella abortus (BA) administration. In
this model, the mice were found to diminish their voluntary
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fixed killed whole BA ring test antigen (7). The advantage of
using this model is that the experiment uses voluntaryexertion,
and that the ability to run for longer periods characterizes
recovery. Thus, the BA-induced mouse model is a good one
for studying the biological underpinnings of chronic fatigue.
We have recently demonstrated the effectiveness of Hochu-
ekki-to (TJ-41), a Japanese herbal medicine for the daily run-
ning activity in the same model of CFS (8). BA administration
was also known to induce changes in cytokine expression char-
acterized by elevated interleukin-10 (IL-10) and interferon-g
(IFN-g) in CD4
þ T cells in mice (9).
Beer is a complex alcoholic beverage made from malt, hops,
water and Brewers’ yeast. Scientific evidence has accumulated
over the past 10 years pointing to the cancer preventive
potential of selected hops-derived beer constituents, i.e.
prenylflavonoids including xanthohumol and isoxanthohumol,
and hop bitter acids (10). Generally, a strain of Brewers’ yeast
such as Saccharomyces pastorianus or Saccharomyces
cerevisiae is applied as yeast for beer fermentation, and after
brewing, a part of the yeast is recovered from the brewing
instrument and used for additional yeast products including
the Brewers’ yeast extract (BYE) as well as the dried yeast.
This extract has been widely used as a food ingredient and a
seasoning. Although BYE includes many soluble components
of vitamin B group, amino acids, peptides and mineral materi-
als, nutritional or pharmacological aspects of BYE have yet to
be fully understood. Since the vitamins and microelements are
frequently utilized for the prevention and therapy for CFS,
BYE is a candidate of the nutritional supplement for CFS.
Puri et al. (11) have reported eicosapentaenoic acid-rich
essential fatty acid supplementation in CFS associated with
symptom remission and structural brain changes. We describe
the effect of BYE on daily running activity in a murine model
of CFS. In addition, the differences in pathological modifica-
tion and cytokine gene expression in spleen between BYE-
treated mice and control are determined.
Materials and Methods
Living Conditions
Female BALB/c mice, 8 weeks of age, were obtained from
Charles River (Kanagawa, Japan), and housed singly in cages
(230 · 100 · 100 mm) including running wheels (230 mm in
diameter), counters showing running wheel activity and water
taps, which were obtained from Natsume Seisakusho Co., Ltd
(Tokyo, Japan). These cages were maintained under a light–
dark photoperiod (10 h versus 14 h) provided by fluorescent
bulbs fitted in the cage floor. We fed all the mice (n ¼ 20)
every day during the course of the experiment. Environmental
air temperature was maintained at 24–25 C. The daily running
activity of mice was defined as the number of wheel complete
turns per 24 h. The running activity was measured at 9 o’clock
when the environmental lighting was turned on. Approval for
this experiment was obtained from the animal experiment
committee in Kanazawa Medical University.
Induction of CFS by BA
Fixed killed whole BA ring test antigen (BA strain 1119-3, lot
no. 302) was obtained from the National Veterinary Services
Laboratories in the United States Department of Agriculture.
CFS was induced by two repeated injections of original BA
antigen solution (0.2 ml per mouse) via the tail vein every
2 weeks (8). In the pilot experiment, we had already confirmed
that the mice with a single administration of BA showed less
running activity for 2–3 weeks after injection and recovery
from the reduced activity thereafter (8). The criteria for estab-
lishing induction of CFS were statistically significant
decreases of the running activity after first or second BA injec-
tion as compared with the baseline levels.
Treatment of Mice with Brewers’ Yeast Extract
We obtained BYE (lot no. 909031) from Asahi Breweries, Ltd
(Tokyo, Japan). The components in BYE are shown in Table 1.
This agent was dissolved in distilled water and diluted with
water to the appropriate concentration. The BYE solution
was administered orally in a dose of 2 g per kg once daily
through a feeding cannula inserted down the throat of the
Table 1. Components of brewing yeast extract used in the study
Components Amount (per 100 g extract)
Vitamin B1 13.11 mg
Vitamin B2 5.10 mg
Vitamin B6 4.73 mg
Pantothenate 4.48 mg
Zinc 6.76 mg
Glutathione 180 mg
Arginine 4.66 g
Lysine 5.36 g
Histidine 1.65 g
Phenylalanine 2.60 g
Tyrosine 0.83 g
Leucine 3.95 g
Isoleucine 3.06 g
Methionine 1.03 g
Valine 3.89 g
Alanine 4.55 g
Glycine 3.25 g
Proline 2.42 g
Glutamic acid 7.44 g
Serine 3.12 g
Threonine 3.07 g
Asparaginic acid 6.90 g
Tryptophan 0.87 g
Cystine 0.58 g
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4 weeks thereafter. The dose of the BYE was determined on
the basis of findings of another research applying the same
BYE for the fatigue mice (12). Untreated mice (n ¼ 10)
were given saline during the same period. The mice in this
experiment were randomly assigned to the BYE-treated or
the control group.
Daily Running Activity, Body Weight and
Survival in Mice
We started to examine the running activity during 2 weeks at
baseline levels after 2 weeks of housing, since the activity
was stabilized after 2–3 weeks of housing (7,8). Daily activity
during 2 weeks after each injection of BA was evaluated in the
mice receiving BYE as compared with that in the untreated
mice. We measured body weight (BW) in both groups weekly
from the start of treatment with the extract to the end of experi-
ment. Survival in both groups was also monitored during the
observation period.
Organ Weights and Pathological Examination in
Spleen and Thymus
The mice in both groups were sacrificed by cervical disloca-
tion 4 weeks after the first BA injection. Ratios of spleen
weight (SW) (mg) to BW (g) (SW/BW), thymus weight
(TW) (mg) to BW (TW/BW), heart weight (HW) (mg) to
BW (HW/BW) and lung weight (LW) (mg) to BW (LW/
BW) as well as the weights of the organs and the body were
assessed between both groups at the time of sacrifice. One
half of spleen and thymus was fixed in 10% buffered formalin
and stained with hematoxylin–eosin; the other half was frozen
and stored at  80 C until analysis of cytokine gene expres-
sion. We performed measurements of the splenic lymphoid
follicular area and thymic medullary area to be expressed as
a percentage of total splenic or thymic area in the long-axis
sections (13). The splenic follicular area and thymic medullary
area were examined in a normal female BALB/c mouse. Each
tissue was evaluated blindly by an experienced pathologist
who had no knowledge of the study design.
Expression Levels of INF-g and IL-10 mRNA in Spleen
RNA extraction for each frozen splenic tissue was performed
as described by the manufacturer (RNeasy Mini Kit, QIAGEN
Inc., Tokyo, Japan). Procedure of DNase was performed dur-
ing the RNA extraction to avoid DNA contaminations. The
total RNA concentrations were determined by measuring the
optical density at 260 and 280 nm. Aliquots of 20 ml RNA
from each tissue were applied for production of cDNA. Com-
parative expression levels of IFN-g (proinflammatory
cytokine) and IL-10 (anti-inflammatory cytokine) mRNA in
spleens from both groups were determined by using real-time
quantitative RT–PCR as described previously (7,8). We
applied TaqMan MGB Probe (Applied Biosystems Inc., CA,
USA) for the RT–PCR. Commercially available kits for
IFN-g and IL-10 RT–PCR (Mm00801778_m1 and
Mm00439616_m1, Applied Biosystems Inc.) were used.
Each threshold cycle number up to 50 cycles (Ct value) within
the RT–PCR was examined for the IFN-g and IL-10 mRNA
levels. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
gene was used as an endogenous internal standard, and was
amplified with specific primers for the number of cycles. A
negative control without template cDNA was always included.
DCt values referred to differences between the Ct values for
each target gene and the GAPDH gene. After confirming that
efficiencies of amplification of each molecule and GAPDH
transcripts were approximately equal, amount of the IFN-g or
IL-10 transcript relative to the GAPDH transcript was determ-
ined using the comparative Ct method described in Perkin
Elmer Applied Biosystems User Bulletin #2 (1997). Data are
expressed as fold-increases relative to the baseline (value ¼ 1)
in spleen from a normal female BALB/c mouse.
Statistical Analyses
Data are expressed as mean values ± SD. Significant changes
of the activity after first or second BA injection as compared
with the baseline levels were evaluated by the paired Student’s
t-test. Data differences between the mice treated with the
yeast extract and the control were analyzed by the unpaired
Student’s t-test. A P-value of <0.05 was considered to be
statistically significant.
Results
Daily Running Activity, Body Weight and
Survival in Mice
Daily running activity in both mouse groups before and after
repeated BA injection is indicated in Fig. 1. Significant
decreases of the activity after first or second BA injection as
compared with the baseline levels were observed in the treat-
ment and control groups, showing the induction of CFS. The
baseline activity and the activity during 2 weeks after the first
BA injection were not significantly different between both
groups (Fig. 1). However, the activity during 2 weeks after
the second BA injection was significantly higher in the group
treated with BYE than in the control (8966 þ 1647 versus
4821 þ 1355, respectively, P < 0.05). There was no signific-
ant difference in BW between both the groups through the
observation course, although a transient decline in BW was
found in the control (Fig. 2). Two mice in the untreated group
died 2 and 7 days after the second BA injection, whereas no
mice in the group treated with BYE died.
Organ Weights and Pathological Examination in
Spleen and Thymus
Ratios of each organ to BW as well as BW, SW, TW, HW and
LW in both groups are shown in Table 2. Significant reduction
in SW was found in the mice treated with BYE as compared
with that in the control (329 ± 73 mg versus 517 ± 98 mg,
eCAM 2006;3(1) 111respectively, P < 0.05), whereas there were no differences in
the weights of other organs between both the groups
(Table 2). SW/BW ratio was significantly lower in the group
treated with BYE than in the untreated group at the time of
sacrifice (15.0 ± 3.4 versus 24.5 ± 4.7, P < 0.05), while
TW/BW, HW/BW and LW/BW ratios were not significantly
different between both the groups (Table 2). The percent fol-
licular area and medullary area were 31 and 28% in spleen
and thymus of the normal female BALB/c mouse. Signific-
antly, increase of splenic follicular area was observed in the
treated mice as compared with that in the untreated group
(24 ± 8% versus 14 ± 6%, respectively, P < 0.05). As shown
in Fig. 3B, the lymphoid follicles were found to be impaired in
spleens of the untreated mice. However, there was no differ-
ence in thymic medullary area between both the groups
(Fig. 3A).
Expression Levels of IFN-g and IL-10 mRNA in Spleen
Comparative expression levels of IFN-g and IL-10 mRNA in
spleen are shown in Fig. 4A and B. The IFN-g and IL-10
mRNA levels in spleens of the mice treated with BYE were
significantly lower than those in the control (7.67 ± 5.97
versus 13.87 ± 4.77 and 5.18 ± 1.36 versus 8.45 ± 1.94 in
IFN-g and IL-10 mRNA levels, respectively, P < 0.05).
Discussion
Vitamins and microelements such as high amounts of vitamins
B, K and essential amino acids are very important for the
prevention and treatment for individuals with fatigue. In a clin-
ical study, a nutritional supplement ‘Nagipol’ made on the
basis of Brewers’ yeast in Russia was applied for the preven-
tion and treatment of CFS patients (14). The results showed
that this food was useful in CFS because of the clinical status
improvement, positively influencing cognitive CNS functions
and symptoms of emotional instability and normalizing blood
biochemical parameters, suggesting recommendation of the
food as preventive medical dietetic means for this pathology.
We have also found the beneficial effect of BYE on daily run-
ning activity in a murine model of CFS. It might be worth
Table 2. Effect of brewing yeast extract on body weight and weight of
organs including spleen, thymus, heart and lungs at the time of sacrifice
BW
(g)
SW
(mg)
TW
(mg)
HW
(mg)
LW
(mg)
Treated mice 22.0 ± 1.9 329 ± 73* 44 ± 7 114 ± 15 158 ± 22
(n ¼ 10) (15.0 ± 3.4*
) (2.1 ± 0.2) (5.2 ± 0.7) (7.2 ± 1.0)
Untreated mice 21.2 ± 2.0 517 ± 98 42 ± 4 111 ± 10 152 ± 20
(n ¼ 8)** (24.5 ± 4.7) (2.0 ± 0.2) (5.1 ± 0.5) (7.1 ± 0.9)
Data are expressed as means ± SD. BW, body weight; SW, spleen weight;
TW, thymus weight; HW, heart weight; LW, lungs weight. Parentheses show
ratio of each organ weight to body weight.
*P < 0.05 compared with spleen weight in the untreated mice.
**Two mice in the untreated group died 2 and 7 days after the second injection
of BA.
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Figure 1. Effect of brewing yeast extract on daily running activity in a mouse
model of chronic fatigue syndrome. Data are expressed as means ± SD. NS,
not significant; BA, Brucella abortus. Daily running activity was defined as
the number of wheel turns per 24 h. Asterisk represents two mice in the
untreated group died 2 and 7 days after the second injection of BA, while no
mice in the treated group died.
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Figure 2. Weekly variation of body weight between different mice from the
start of treatment with brewing yeast extract to the end of experiment. Data
are expressed as means ± SD. NS, not significant; BA, Brucella abortus.
Asterisk represents two mice in the untreated group died 2 and 7 days after
the second injection of BA, while no mice in the treated group died.
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CFS or fatigue subjects with other various disorders in future
clinical study.
Previous study reported clinical aspects of 21 individuals
with chronic brucellosis (15). Seventeen patients suffered
from chronic disease and had no history of any acute episode
of brucellosis. The most common symptoms in the patient
population were tiredness, fatigue, depression, arthralgia and
muscular pains. Most of these subjects had already been
receiving psychiatric treatment. Clinical examination was lar-
gely negative, but lymphadenopathy was found in nine cases.
Based on these clinical manifestations, the fatigue induced
by BA administration which was used in the present research
might be applicable to a mouse model of CFS.
Figure 3. Percentages of splenic lymphoid follicular area and thymic medul-
lary area between different mice (A) and pathological findings of the follicular
area in spleen (B, upper image in the treated mice and lower image in the con-
trol). Data are expressed as means ± SD. NS, not significant; BA, Brucella
abortus. Arrows show the follicular area in the spleen.
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Figure 4. Comparative expression levels of interferon-g (INF-g)( A) and
interleukin-10 (B) mRNA in spleen between different mice. Data are expressed
as means ± SD. The INF-g and interleukin-10 mRNA levelswere calculatedas
comparative values, which were normalized to the cytokines’ mRNA in the
spleen from normal female BALB/c mouse (value ¼ 1).
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brucellosis (16,17). Inhibition of in vitro lymphocyte prolifera-
tion by brucella-activated macrophages was also found during
experimental murine brucellosis (18). Increase of SW and SW/
BW ratio after the repeated BA injection was observed
together with decrease of splenic follicular area in the present
study, and there was significant improvement of SW, SW/BW
ratio and splenic follicular area in the treated group, suggesting
that the measurement of splenic enlargement and follicular
area might be useful to monitor improvement of immune
stimulation during treatment.
We found significant decreases of IFN-g (proinflammatory
cytokine) and IL-10 (anti-inflammatory cytokine) mRNA
levels in the spleens of the mice treated with BYE as compared
with those of the control. Svetic et al. (9) described that simul-
taneous elevation in Th1 cytokine, IFN-g, and Th2 cytokine,
IL-10, appeared in type 1 immune responses after the BA
injection. Reduced expression of IL-2 and -4 as well as
increased expression of IL-10 were found in another study
using BA (7). Although it is uncertain whether IL-10 plays a
role in suppressing severity of inflammatory response medi-
ated by IFN-g, BYE treatment could contribute to normaliza-
tion of host immune responses in the CFS mouse model,
suggesting that these cytokines’ expression might be a
biomarker in the treatment for CFS.
There are few investigations showing the effectiveness
of alternative and complementary approaches including
nutritional supplements for subjects with CFS. Cox et al.
(19) reported that magnesium treatment might improve the
well-being of the CFS patients because of low red blood cell
magnesium in CFS. In a placebo-controlled study, there were
no significant differences in symptoms between the group
treated with red-cell membrane essential fatty acids and pla-
cebo in CFS (20). In addition, no significant difference was
apparent between response to placebo and that to liver extract
containing folic acid and cyanocobalamin (21). In our study,
daily running activity during 2 weeks after the second BA
injection was significantly higher in the group treated with
BYE in a dose of 2 g per kg per day than in the control.
Significantly lowered SW and SW/BW ratio was observed in
the treated mice together with increase of splenic follicular
area. There were decreased IFN-g and IL-10 mRNA levels
in spleens of the treated group. These data suggest that BYE
treatment might possess a preventive effect on the marked
reduction in running activity following the repeated BA injec-
tion via normalization of host immune responses, although the
optimum dose and the appropriate time of initiating the treat-
ment with BYE have not been established in this study. Further
investigations are required to elucidate these ancesus. l-argin-
ine increases nitric oxide (NO) release into circulation via
endothelial NO synthase. NO suppresses the activation of the
key gene of inflammation, nuclear factor kappa B (22),
and might account for the beneficial effect of BYE.
Therefore, we should consider administering l-arginine alone
in a future study.
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